Thrombin Inhibitors (Non-Heparinoid)

Thrombin inhibitors (non-heparinoid), more formally known as direct thrombin inhibitors (DTIs), are an anticoagulant drug class distinct from heparin and heparinoids because they do not rely on endogenous antithrombin to exert their activity

Thrombin inhibitors (non-heparinoid), more formally known as direct thrombin inhibitors (DTIs), are an anticoagulant drug class distinct from heparin and heparinoids because they do not rely on endogenous antithrombin to exert their activity

These agents—including parenteral drugs such as argatroban and bivalirudin, as well as the oral agent dabigatran—bind directly and reversibly to the active site or exosite of both circulating and clot-bound thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting thrombin-induced platelet activation

These agents—including parenteral drugs such as argatroban and bivalirudin, as well as the oral agent dabigatran—bind directly and reversibly to the active site or exosite of both circulating and clot-bound thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting thrombin-induced platelet activation

These agents—including parenteral drugs such as argatroban and bivalirudin, as well as the oral agent dabigatran—bind directly and reversibly to the active site or exosite of both circulating and clot-bound thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting thrombin-induced platelet activation Clinically, this class serves as an essential therapy for managing thromboembolism in patients with heparin-induced thrombocytopenia, providing procedural anticoagulation du...

Clinically, this class serves as an essential therapy for managing thromboembolism in patients with heparin-induced thrombocytopenia, providing procedural anticoagulation during percutaneous coronary intervention, and reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation or deep vein thrombosis

Clinically, this class serves as an essential therapy for managing thromboembolism in patients with heparin-induced thrombocytopenia, providing procedural anticoagulation during percutaneous coronary intervention, and reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation or deep vein thrombosis